Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo

Charlotte Ngô, Carole Nicco, Leconte M, Mahaut Leconte, Chéreau C, Christiane Chéreau, Sylviane Arkwright, Arkwright S, S Arkwright, Marie-Cécile Vacher-Lavenu, Vacher-Lavenu MC, Marie‐Cécile Vacher‐Lavenu, Weill B, Bernard Weill, Charles Chapron, Chapron C, Frédéric Batteux
The Journal of Pathology · 2010 · vol. 222(2) , pp. 148–157 · doi:10.1002/path.2756 · PMID:20821752 · W2010952228
article OA: closed CC0 ⤵ 59 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This study found that the ERK pathway is activated in endometriosis, and protein kinase inhibitors significantly reduced endometriotic cell proliferation in vitro and implant growth in vivo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis affects 6-10% of women in their reproductive years, causing chronic pelvic pain and infertility. Its pathogenesis remains poorly understood and current treatments, based on hormonal therapy or surgery, are often insufficient. The purpose of our study was to investigate the role of the ERK pathway in the development of endometriosis and to test the effects of protein kinase inhibitors on the proliferation of endometriotic cells in vitro and in vivo. We studied ex vivo human endometrial and endometriotic cells in culture. Stromal and epithelial cells were extracted from endometrial and endometriotic biopsies from patients with endometriosis and from patients without endometriosis. The ERK pathway was explored by western blot on cell lysates and by ELISA on total crushed specimens of endometrium. Cells in culture were treated with A771726, PD98059, and U0126. Human endometriotic lesions were implanted in nude mice. Mice were treated with A771726, leflunomide, PD98059, U0126 or PBS during 2 weeks before sacrifice and extraction of the endometriotic implants for histological examination. We found that the ERK pathway was significantly activated in endometriotic cells and in endometrial cells from patients with endometriosis compared to endometrial cells of control patients, both by ELISA and by western blot. This phenomenon was associated with an increased proliferation of endometriotic cells compared to endometrial cells. Treating endometriotic cells with A771726, PD98059 or U0126 abrogated the phosphorylation of ERK and significantly decreased the cellular proliferation in vitro. In vivo, A771726, leflunomide, PD98059, and U0126 controlled the growth of endometriotic implants in the mouse model of endometriosis. Our study shows that protein kinase inhibitors could be new candidates to treat endometriosis. However, further studies are needed to evaluate their effects and tolerability in humans.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paininfertility

MeSH descriptors

Endometriosis Endometrium Protein Kinase Inhibitors Adult Animals Cell Proliferation Cell Proliferation Cells, Cultured Disease Models, Animal Disease Progression Drug Evaluation, Preclinical Endometriosis Endometriosis Endometriosis Endometrium Endometrium Endometrium Endometrium Enzyme-Linked Immunosorbent Assay Enzyme-Linked Immunosorbent Assay

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (51)

Cited by (50)

Source provenance

europepmc
last seen: 2026-08-20T06:14:21.026120+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:00.782903+00:00
License: CC0 · commercial use OK